Eric Venker sold $120k of IMVT
Chief Executive Officer at Immunovant, Inc.. 3,506 shares at an average of $34.11, traded Oct 2, 2026, filed Oct 5, 2026.
Score components
- +25RoleCEO
- +10Trade size$120k at market
- 0Share of holdings soldSold 1.3% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-26-000110, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock | +92,187 | $14.46 | $1.3M | 346,467 | 7 d ago |
| Oct 1, 2026 | DDisposition to issuer Common Stock | -85,886 | $33.65 | $2.9M | 260,581 | 7 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock | -3,506 | $34.11 | $120k | 257,075 | 7 d ago |
| Oct 1, 2026 | MOption exercise Capped Value Appreciation Rightsderivative | -92,187 | $0.00 | $0 | 921,875 | 7 d ago |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| 36Weak | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 29Weak | Immunovant, Inc. | Michael Geffner Chief Medical Officer | $43k 2,385 shares | -1% | |
| 30Weak | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $51k 2,805 shares | -1% | |
| 23Weak | Immunovant, Inc. | Michael Geffner Chief Medical Officer | $20k 1,160 shares | -1% | |
| 28Weak | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $26k 1,519 shares | -1% | |
| 36Weak | Immunovant, Inc. | Michael Geffner Chief Medical Officer | $35k 2,349 shares | -1% | |
| 35Weak | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $28k 1,925 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.